NCT06388083 - A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

January 31, 2028

Conditions

STGD1Stargardt Disease 1

Interventions

DRUG

Tinlarebant

5 mg tablet

DRUG

Placebo

Placebo tablets

Trial Locations (14)

11590

RECRUITING

Belite Study Site - US10, Westbury

19107

NOT_YET_RECRUITING

Belite Study Site - US07, Philadelphia

27705

RECRUITING

Belite Study Site - US02, Durham

33136

RECRUITING

Belite Study Site - US06, Miami

55905

RECRUITING

Belite Study Site - US04, Rochester

75231

RECRUITING

Belite Study Site - US03, Dallas

85020

RECRUITING

Belite Study Site - US08, Phoenix

92093

RECRUITING

Belite Study Site - US05, La Jolla

94158

RECRUITING

Belite Study Site - US09, San Francisco

02115

RECRUITING

Belite Study Site - US01, Boston

Unknown

RECRUITING

Belite Study Site, Kobe

RECRUITING

Belite Study Site, Kyoto

RECRUITING

Belite Study Site, Tokyo

RECRUITING

UK01 Belite Study Site, London